Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sacituzumab Tirumotecan HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (53)
Sacituzumab Tirumotecan Inetetamab	Fudan University	P2	CCC (53)
Sacituzumab Tirumotecan Metastatic Breast Cancer ( HER2 Negative)	Fudan University	P2	CCC (53)
Sacituzumab Tirumotecan SKB264	Fudan University	P2	CCC (53)
Serplulimab Moderately Hypofractionated Radiotherapy	Fudan University	P2	CCC (53)
Serplulimab pMMR/MSS	Fudan University	P2	CCC (53)
Serplulimab Serplulimab	Fudan University	P2	CCC (53)
Shr-1167 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-1167 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Shr-1701 Chemoradiotherapy	Fudan University	P2	CCC (53)
Shr-1701 Castration-Resistant Prostate Carcinoma	Fudan University	P2	CCC (53)
Shr-2554 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Fudan University	P2	CCC (53)
Shr-4602 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-4602 Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
Shr-4602 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Shr-4602 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Shr-6209 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-6209 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Shr-A1811 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-A1811 Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
Shr-A1811 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Shr-A1921 Metastatic Malignant Neoplasm In The Brain	Fudan University	P2	CCC (53)
Shr-A1921 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-A1921 Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
Shr-A1921 Hormone Receptor-Positive Breast Cancer	Fudan University	P2	CCC (53)

Showing 351 to 375 of 615 assets

PreviousPage 15 of 25Next